Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-06-14
2011-06-14
Vivlemore, Tracy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
07960358
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA desaturase are provided.
REFERENCES:
patent: 5741666 (1998-04-01), Tartaglia
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6030837 (2000-02-01), McKay et al.
patent: 6077672 (2000-06-01), Monia et al.
patent: 6261840 (2001-07-01), Cowsert et al.
patent: 6355635 (2002-03-01), Elliott et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2002/0151018 (2002-10-01), Prouty et al.
patent: 2003/0064950 (2003-04-01), Ntambi et al.
patent: 2003/0083282 (2003-05-01), Crooke et al.
patent: 2003/0157552 (2003-08-01), Hayden et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 238 198 (1987-09-01), None
patent: WO 96/18736 (1996-06-01), None
patent: WO 99/63979 (1999-12-01), None
patent: WO 99/67378 (1999-12-01), None
patent: WO 00/09754 (2000-02-01), None
patent: WO 01/62954 (2001-08-01), None
patent: WO 03/012031 (2003-02-01), None
patent: WO 03/070885 (2003-08-01), None
patent: WO 2004/047746 (2004-06-01), None
patent: WO 2005014607 (2005-02-01), None
Miyazaki et al. (2000) “The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1” J. Biol. Chem. 275:30132-138.
Bennett et al. (1999) “Antisense oligonucleotides as a tool for gene functionalization and target validation” Biochimica Biophysica Acta 1489:19-30.
Bakker et al. (2000) “Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and β-cell failure?” Atherosclerosis 148:17-21.
Bhatti (2001) “Lipid profile in obesity” J. Ayub. Med. Coll. Abbottabad. Jan.-Mar.;13(1):31-3.
Diot et al., “Stearoyl-CoA desaturase 1 coding sequences and antisense RNA affect lipid secretion in transfected chicken LMH hepatoma cells,”Archives Biochem. and Biophys.380(2):243-250 (2000).
Ahuja et al., “Differential Effects of Rexinoids and Thiazolidinediones on Metabolic Gene Expression in Diabetic Rodents,”Mol. Pharmacol.(2001) 59:765-773.
Agrawal et al., “Antisense Therapeutics: is it simple as complementary base recognition?,”Molecular Medicine Today(2000) 6:72-81.
Bene et al., “Cloning and Characterization of the Human Stearoyl-CoA Desaturase Gene Promotor: Transcriptional Activation by Sterol Regulartory Element Binding Protein and Repression by polyunsaturated Fatty Acids and Cholesterol,”Biochemistry and Biophysical Research Communications(2001) 284:1194-1198.
Branch, A.D., “A good antisense molecule is hard to find,”TIBS(1998) 45-50.
Diot et al., “Stearoyl-CoA Desaturase 1 Coding Sequences and Antisense RNA Affect Lipid Secretion in Transfected Chicken LMH Hepatoma Cells,”Archives of Biochemistry and Biophysics(2000) 380(2):243-250.
Green et al., “Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease,”Am. Coll. Surg.(2000) 93-105.
Jen et al., “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies,”Stem Cells(2000) 18(5): 307-319.
Jones et al., “Adipose tissue stearoyl-CoA desaturase mRNA is increased by obesity and decreased by polyunsaturated fatty acids,”Am. J. Physiol.(1996) 271(1):E44-49.
Kim et al., “Differential regulation of the stearoyl-CoA desaturase genes by thiazolidinediones in 3T3-L1 adipocytes,”J. Lipid Res.(2000) 41(8):1310-1316.
Li et al., “Partial Characterization of a cDNA for Human Stearoyl-CoA Desaturase and Changes in its mRNA Expression in Some Normal and Malignant Tissue,”Int. J. Cancer(1994) 57:348-352.
Milner, N. et al., “Selecting effective antisense reagents on combinatorial oligonucleotide arrays,”Nature Biotechnology(1997)15:537-541.
Ntambi, J.M., “The Regulation of Stearoyl-CoA Desaturase (SCD),”Prog. Lipid Res.(1995) 34(2):139-150.
Ntambi, J.M., “Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol,”J. Lipid Res.(1999) 40:1549-1558.
Opalinska, J., “Nucleic-Acid Therapeutics: Basic Principles and Recent Applications,”Nature Reviews Drug Discovery(2002) 1:503-514.
Sessler et al., “Regulation of Stearoyl-C-A Desaturase 1 mRNA Stability by Polyunsaturated Fatty Acids in 3T3-L1 Adipocytes,”J. Biol. Chem(1996) 271(947):29854-29858.
Taylor, M. et al., “Antisense Oligonucleotides: A Systematic High-Throughput Approach to Target Validation and Gene Function Determination,”DDT(1999) 4(12):562-567.
Zhang et al., “Human stearoyl-CoA desaturase: alternative transcripts generated from a single gene by usage of tandem polyadenylation sites,”Biochem. J.(1999) 340:255-264.
Zhang et al., “Isolation and characterization of the human stearoyl-CoA desaturase gene promoter: requirement of a conserved CCAATcis-element,”Biochem. J.(2001) 357:183-193.
Chin “On the Preparation and Utilization of Isolated and Purified Oligonucleotides” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
Crooke et al., “Basic Principles of Antisense Therapeutics” Antisense Research and Application (1998) Chapter 1:1-50.
New England Biolabs 1998/99 Catalog (cover page and pp. 121 and 284).
Reynolds et al., “Rational siRNA design for RNA interference” Nature Biotechnology (2004) 22(3):326-330.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.
Bhanot Sanjay
Dobie Kenneth W.
Geisler John G.
Graham Mark J.
ISIS Pharmaceuticals Inc.
Jones Day
Vivlemore Tracy
LandOfFree
Antisense modulation of stearoyl-CoA desaturase expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of stearoyl-CoA desaturase expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of stearoyl-CoA desaturase expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2725500